Figure 4 . CXCL16 worsened cecal ligation and puncture (CLP)-induced nonsevere sepsis. (A) Survival of CLP mice (n = 12 per group) after treatment with recombinant CXCL16 protein in the absence or presence of CLP-induced nonsevere sepsis. Murine recombinant CXCL16 protein was administered intraperitoneally at 0.5–1.0 μg/injection immediately after nonsevere CLP, and PBS was used as a control. Comparison between groups was performed using Kaplan-Meier analysis followed by log-rank tests. Results are representative of three independent experiments. p <0.001 when compared with septic mice treated with PBS control. (B) Representative examples of hematoxylin and eosin–stained lung, liver, and kidney tissues from nonsevere CLP mice (n = 6) treated with or without recombinant CXCL16 (0.5 μg/injection). (C) Histological scores for lung, liver, and kidney in nonsevere CLP mice (n = 6) treated with or without recombinant CXCL16 (0.5 μg/injection). p <0.05,p <0.001when compared with septic mice treated with PBS control (Mann-Whitney U test). (D) ALT, AST, LDH, and creatinine levels in nonsevere CLP mice (n = 6), treated with or without recombinant CXCL16 (0.5 μg/injection). p <0.001 when compared with septic mice treated with PBS control (Mann-WhitneyU test).